Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Race Oncology Ltd. ( (AU:RAC) ).
Racura Oncology Ltd has applied to the ASX for quotation of 32,658 new fully paid ordinary shares, to be issued on 23 December 2025 following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted capital reflects ongoing utilisation of equity-linked incentives or financing arrangements, marginally expanding the company’s shareholder base and providing additional capital flexibility to support its oncology drug development programs.
More about Race Oncology Ltd.
Racura Oncology Ltd (ASX: RAC) is a biotechnology company operating in the oncology sector, focused on developing cancer therapies. The company targets unmet medical needs in cancer treatment, aiming to advance novel oncology drug candidates through clinical and commercial pathways for global markets.
Average Trading Volume: 439,953
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$489.9M
Learn more about RAC stock on TipRanks’ Stock Analysis page.